Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
118
resultados
Última actualización
11/04/2026 [06:57:00]
Resumen de: US20260096784A1
0000 A computer-implemented method and system reduce the likelihood of nocturnal hypoglycemia by predicting overnight glucose level and providing personalized recommendations. Glucose-derived features from continuous glucose monitor (CGM) data, physical-activity features, and demographic features are extracted and input into a neural network configured to output parameters of a probability distribution representing a predicted minimum overnight glucose value and an associated predictive uncertainty. Based on the network output, a probability that the glucose level will fall below a specified hypoglycemic level within an upcoming sleep period is computed and compared to a risk threshold. When the probability meets or exceeds the risk threshold, a mobile computing device displays a personalized bedtime snack recommendation selected to mitigate the predicted hypoglycemia event. The approach integrates physiological data, individualized modeling, and decision support to provide actionable guidance for avoiding nocturnal hypoglycemia.
Resumen de: AU2026202087A1
Methods and devices include automated coaching for management of glucose states by receiving a user's glucose levels using a continuous glucose monitoring (CGM) device, determining a time in range (TIR) value, determining a TIR state, receiving a glucose variability (GV) value, determining a GV state, determining a starting state based on the TIR state and the GV state, determining that the starting state corresponds to a non-ideal state, generating an optimized pathway to reach an ideal state based on one or more account vectors such as addressing self- management behavior including food, activity, and medication use. The optimized pathway may further be based on computer detection and classification of significant events of interest over time.20 ar a r
Resumen de: US20260096738A1
0000 According to an aspect, there is provided a computer-implemented method (200) of determining a concentration of glucose in a subject's blood, the method comprising: acquiring (202) first measurement data indicative of a response resulting from an electromagnetic (EM) signal interacting with the subject's blood in a body part of the subject; acquiring (204) second measurement data indicative of at least one parameter associated with the subject; and using (206) a predictive model to infer a concentration of glucose in the subject's blood from the first measurement data and the second measurement data, the predictive model having been trained to infer a concentration of glucose in the subject's blood from the first measurement data and the second measurement data.
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Resumen de: AU2024350322A1
Embodiments disclosed herein relate to systems and methods for adapting ambulatory infusion pump systems to operate with different types of continuous glucose monitoring (CGM) sensors. Infusion pump systems as disclosed herein can include software configured to store characteristics for different types of CGM sensors and can interface with a given type of CGM sensor based on specific characteristics and requirements of the given type of sensor.
Resumen de: US20260096750A1
A device for continuously monitoring glucose levels in a patient includes a lead assembly in electrical communication with an electronics assembly. The electronics assembly is configured to be positioned in the subcutaneous tissue and the lead assembly is configured to be positioned in a vessel of the patient, such as in a vein or in an epidural space. The lead assembly has a lumen, and includes at least one electrode in electrical communication with the electronics assembly.
Resumen de: EP4723123A1
Systems, devices, and techniques are disclosed for providing personalized insulin dosage recommendations for a patient. In some aspects, a method includes generating a physiological model for estimating glucose values of the patient based on historical data, the historical data comprising glucose value history and insulin dosage history for a time window during which the patient consumed a plurality of meals. The method also may include estimating, using the physiological model and the historical data, an impact of the plurality of meals on the glucose values of the patient, and receiving a first meal size indication of a first meal for consumption by the patient. The method may also include outputting a first meal bolus insulin dose recommendation based on the impact of the plurality of meals on the glucose values of the patient and the first meal size indication.
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Resumen de: EP4721659A2
0001 Devices are provided for measurement of an analyte concentration, e.g., glucose in a host. The device can include a continuous analyte sensor 34 configured to generate a signal associated with a concentration of an analyte, a reference electrode 30, and a sensing membrane 32 located over the working electrode 38. The sensing membrane comprises a diffusion resistance domain configured to control a flux of the analyte therethrough. The diffusion resistance domain comprises one or more zwitterionic compounds and a base polymer comprising both hydrophilic and hydrophobic regions.
Resumen de: US20260095261A1
Method, system and computer program product for providing real time detection of analyte sensor sensitivity decline is continuous glucose monitoring systems are provided.
Resumen de: AU2026201970A1
MARKED-UP COPY MARKED-UP COPY Disclosed are systems and methods for generating graphical displays of analyte data and/or health information. In some implementations, the graphical displays are generating based on a self-referential dataset that are modifiable based on identified portions of the data. The modified graphical displays can indicate features in the analyte data of a host. ar a r
Resumen de: AU2026201971A1
Systems and methods are provided to provide guidance to a user regarding management of a physiologic condition such as diabetes. The determination may be based upon a patient glucose concentration level. The glucose concentration level may be provided to a stored model to determine a state. The guidance may be determined based at least in part on the determined state. ar a r
Resumen de: US20260091175A1
The invention discloses a drug delivery system with graphical user interface comprises a detection device, for detecting the blood glucose level of the user; an infusion device, for infusing a drug into the user's body; and a control device, wirelessly communicated with the detection device and the infusion device, the control device controlling the drug delivery of the infusion device, and the control device provided with a graphical user interface, the graphical user interface comprising a main screen, the main screen comprising an insulin information display area and a blood glucose information display area, wherein the insulin information display area comprising insulin infusion status information, the graphical user interface displays the insulin infusion status information in a graphical and/or textual manner, to facilitate the user to intuitively know the insulin infusion status information and blood glucose information at that time.
Resumen de: AU2026202005A1
Methods, devices, and kits are provided for determining a recommended insulin dose to be administered to user based upon analyte data determined by an analyte sensor. ar a r
Resumen de: WO2026067891A1
A compensation method and device for a continuous glucose monitor includes: acquiring a real-time glucose value of a user continuously(S101); determining a user type and a glucose trend type according to the real-time glucose value, where the user type includes at least a first user type and a second user type(S102); determining, based on the real-time glucose value, whether a compensation start condition is satisfied; starting a compensation algorithm if the compensation start condition is satisfied(S103); determining a compensation formula based on the real-time glucose value, the glucose trend type, and the user type(S104); and obtaining, based on the real-time glucose value and the compensation formula, a compensated glucose value until a compensation stop condition is satisfied(S105).
Resumen de: WO2026065646A1
Disclosed are a biocompatible film for a biosensor and a glucose sensor. The biocompatible film is prepared by coating a film solution by means of a coating process. The film solution comprises a cofactor-grafted polymer, an organic solvent, and a buffer solution. An end portion of each branch of the cofactor-grafted polymer has a cofactor grafted thereto. The backbone of the cofactor-grafted polymer is one or more of polyurethane, polyvinyl alcohol, a polyvinyl alcohol derivative, polyvinylpyrrolidone, a polyvinylpyrrolidone derivative, polyvinylpyridine, and a polyvinylpyridine derivative. The branches of the cofactor-grafted polymer are one or more of acetic acid, butyric acid, ethyl butyrate, caproic acid, and ethyl hexanoate. The biocompatible film can achieve precise regulation of chemical substance permeability, expand the linear detection range of the biosensor for chemical substances, and provide the cofactors required during chemical substance detection, thereby improving the stability and durability of the biosensor.
Resumen de: AU2026201994A1
22510489_1 (GHMatters) P117930.AU.1 Provided are a system and method for an artificial pancreas having multi-stage model predictive control to minimize and/or prevent occurrence of hypoglycemia associated with Type 1 diabetes. The control implements predictive modeling of a probability of glucose uptake associated with exercise based on at least one exercise 5 profile for a subject with Type 1 diabetes. Based on the probability, the control implements an automatic adjustment of basal insulin infusion to counteract a risk of exercise-induced hypoglycemia in advance of the subject engaging in the exercise. The control further implements adjustment of such infusion based on real-time signaling of exercise likely to induce hypoglycemia. Prior to consumption of a meal, the control 10 further implements adjustment of a meal-time bolus so as to account for the effect of delay in glucose uptake resulting from exercise previously engaged in by the subject. Consequently, the control acts to minimize and/or prevent hypoglycemia from occurring both during and immediately after the subject engages in exercise. ar a r
Resumen de: AU2026201926A1
22514182_1 (GHMatters) P118105.AU.1 Embodiments relate to an adaptive glycemia monitoring and forecasting system that includes an event monitor configured to receive blood glucose levels of an individual or information about an activity performed by the individual, and generate an event output. The system includes a control module configured to pull observation data, predictor variables, and population estimated vector of covariate weightings coefficients from a database, and generate updated estimated vector of covariate weightings coefficients for the individual user based on the event output. The updated estimated vector of covariate weightings coefficients are determined by a cross-entropy loss objective function. The updated estimated vector of covariate weightings coefficients are used to predict at least one or more of a predicted hypoglycemia state, a predicted normal glycemia state, or a predicted hyperglycemia state for the individual user. the individual user. ar a r
Resumen de: WO2026071284A1
A ring-structured non-invasive blood glucose sensor according to the present invention comprises: a transmission unit which is provided in a first ring structure, and which generates electromagnetic waves and irradiates same toward the center of the first ring structure; an active element which is provided in a second ring structure that is smaller than the first ring structure and is disposed inside the first ring structure, and which amplifies the electromagnetic waves irradiated by the transmission unit so that the amplified electromagnetic waves are directed toward an object to be inspected disposed inside the second ring structure; a reception unit which is provided to be spaced apart from the transmission unit in the first ring structure, and which receives electromagnetic waves reflected or scattered from the object to be inspected; and a conductor, which is disposed to be adjacent to the first ring structure and the second ring structure, propagates the electromagnetic waves amplified by the active element toward the object to be inspected, by virtue of a space defined by a conductor, and strengthens a resonance phenomenon by strengthening an electromagnetic field within the defined space.
Resumen de: AU2024280120A1
Blood glucose level measurement includes a light source configured to irradiate light to a subject; a monochrome part configured to separate wavelength components of the light that is reflected and scattered from the subject; a light receiver configured to receive the light transmitted via the monochrome part and to generate electrical signals based on the received light; and a processor configured to extract information on the blood glucose level of the subject based on a frequency shift of the light due to the Raman effect.
Resumen de: EP4717171A2
According to the present disclosure, an applicator for a continuous blood glucose measurement device, the applicator being operated by attaching a body attachment unit to the body of a user, the body attachment unit including a sensor member which is inserted into the body of the user in order to measure the blood glucose, comprises: a main case; a plunger to which the body attachment unit is detachably coupled and which is installed in the main case to be movable from a first position to a second position so that the body attachment unit can be discharged to the outer direction of the main case; a needle which is detachably coupled to the body attachment unit so as to be inserted into the body of the user along with the sensor member; and a needle separating unit which separates the needle from the body of the user by moving the needle in the direction opposite to the discharge direction of the plunger, wherein the needle separating unit includes a locking unit which can be assembled with the plunger in the manner of being engaged with one side of the plunger.
Resumen de: US12588838B1
Introduced here are diabetes management platforms able to examine glucose measurements associated with a subject to discover patterns indicative of similar behaviors/circumstances. More specifically, a diabetes management platform can acquire multiple data series generated by a glucose monitoring device that monitors the blood glucose level of an individual over multiple time intervals. The diabetes management platform can then apply a similarity algorithm to produce a distance measure (also referred to as a “similarity measure”) for each data series. For example, the diabetes management platform may, for each data series, perform dynamic time warping to produce a distance measure with respect to each of the other data series. The diabetes management platform can identify patterns indicative of similar behaviors/circumstances based on these distance measures.
Resumen de: EP1000000A1
The invention relates to an apparatus (1) for manufacturing green bricks from clay for the brick manufacturing industry, comprising a circulating conveyor (3) carrying mould containers combined to mould container parts (4), a reservoir (5) for clay arranged above the mould containers, means for carrying clay out of the reservoir (5) into the mould containers, means (9) for pressing and trimming clay in the mould containers, means (11) for supplying and placing take-off plates for the green bricks (13) and means for discharging green bricks released from the mould containers, characterized in that the apparatus further comprises means (22) for moving the mould container parts (4) filled with green bricks such that a protruding edge is formed on at least one side of the green bricks.
Resumen de: US20260083909A1
A reinforcement learning process with self attention is used for insulin dosing decisions in an automated medical system. The State-Action-Reward-Next State (SARS) sequence is used. The state represents the current condition, including recent continuous glucose monitoring readings, insulin doses, meal information, and potentially other relevant factors like time of day or physical activity levels. Based on this state, the agent takes an action by deciding on an insulin dose. It then receives a reward, a numerical value quantifying the quality of the action, based on resulting glucose levels and their proximity to the target range. This leads to a new state, and the process repeats. Through this iterative process, the algorithm updates the neural network weights, allowing the agent to learn which actions lead to better outcomes in different states.
Nº publicación: WO2026064554A1 26/03/2026
Solicitante:
KODIAK SCIENCES INC [US]
KODIAK SCIENCES INC
Resumen de: WO2026064554A1
Provided herein are methods of treating various eye disorders, including, for example, wet age-related macular degeneration (wAMD) or diabetic retinopathy (DR), using an anti-VEGF therapy, such as an anti-VEGF antibody conjugate.
BOPI
Sede Electrónica
